Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) have been given an average recommendation of “Hold” by the five analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $5.80.
A number of research analysts recently weighed in on LXRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 21st. Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 8th. Citigroup increased their price objective on shares of Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the company a “buy” rating in a research report on Monday, November 9th. Finally, Cantor Fitzgerald started coverage on shares of Lexicon Pharmaceuticals in a research note on Monday, September 28th. They issued an “overweight” rating and a $8.00 price objective for the company.
Read Our Latest Research Report on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Price Performance
NASDAQ:LXRX opened at $1.75 on Tuesday. The company has a market capitalization of $779.15 million, a P/E ratio of -12.50 and a beta of 1.10. The business’s 50-day moving average is $1.76 and its 200 day moving average is $1.89. The company has a current ratio of 10.62, a quick ratio of 10.56 and a debt-to-equity ratio of 0.32. Lexicon Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $2.68.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $11.25 million for the quarter, compared to the consensus estimate of $4.14 million. Lexicon Pharmaceuticals had a negative return on equity of 35.76% and a negative net margin of 161.80%. On average, equities research analysts forecast that Lexicon Pharmaceuticals will post -0.16 earnings per share for the current fiscal year.
Insider Transactions at Lexicon Pharmaceuticals
In related news, CEO Michael Exton purchased 30,064 shares of the stock in a transaction that occurred on Friday, November 6th. The stock was bought at an average cost of $1.66 per share, for a total transaction of $49,906.24. Following the completion of the transaction, the chief executive officer directly owned 328,496 shares in the company, valued at $545,303.36. This represents a 10.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.00% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its stake in shares of Lexicon Pharmaceuticals by 143.4% in the third quarter. Goldman Sachs Group Inc. now owns 1,182,049 shares of the biopharmaceutical company’s stock valued at $2,216,000 after acquiring an additional 696,503 shares during the period. Pictet Asset Management Holding SA purchased a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth about $41,000. Profund Advisors LLC boosted its stake in shares of Lexicon Pharmaceuticals by 600.8% during the 3rd quarter. Profund Advisors LLC now owns 340,479 shares of the biopharmaceutical company’s stock worth $638,000 after purchasing an additional 291,893 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at about $66,000. Finally, WINTON GROUP Ltd grew its holdings in Lexicon Pharmaceuticals by 69.4% during the 2nd quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 17,700 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.
See Also
- Five stocks we like better than Lexicon Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
